



May 15, 2023

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Press release for unaudited financial results for the quarter ended March 31, 2023

We are enclosing herewith the Press Release, regarding the Unaudited Financial Results for the quarter ended March 31, 2023, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary



Procter & Gamble Health Announces Third Quarter Results showing 16% Growth in Net Profits

*Sales of ₹316.28 Crores and PAT of ₹59.2 Crores for quarter ended March 31, 2023
Sales for the quarter up by 21%*

Mumbai, May 15, 2023: Procter & Gamble Health Limited announced today its financial results for the quarter ended March 31, 2023. The Company delivered total sales of ₹ 316.3 crores for the quarter ended March 31, 2023, vs ₹ 262.2 crores, a year ago, up by 21%. The Profit After Tax (PAT) was ₹ 59.2 crores, up by 16% vs a year ago. Sales for the nine-month period ending March 31, 2023, was ₹ 912.8 crores vs ₹ 803.2 crores a year ago. PAT for a nine-month period was ₹ 199.7 crore vs ₹ 151.4 crore a year ago, despite the high inflationary pressures

Mr. Milind Thatte, Managing Director, P&G Health India, said, “We continue to register a consistent growth in this quarter despite a challenging macro-economic environment. This has been made possible through our integrated growth strategies of expanded reach and improved productivity, while we continue to create awareness among our patients and consumers alike. The cornerstone of our approach continues to be our robust product line, which helps meet the rising demand for daily supplements, thereby helping us deliver the 6th consecutive quarter of strong growth. Our focus brands, Evion, Neurobion and Livogen continue to perform exceptionally well. The quarter also saw Neurobion regain its position as India’s No. 1 Nerve Care Brand, while Livogen’s exceptional performance continued behind the award winning campaign ‘Na Na Anemia’ with Diagnostic camps across the country. Under our flagship CSR Program, SEHAT, in partnership with Tata Trust’s ‘Yes! To Poshan’ Program, we continued to showcase our commitment towards the cause of maternal & child health.”

“The quarter also saw us receive various prestigious recognitions. We are thankful to the CSR Summit and Awards 2023, CII, Exchange4media and Obesity International for recognizing our Corporate Social Responsibility and Consumer Awareness efforts. These recognitions have further fueled our passion and commitment to serve Indian consumers and help them live healthier lives,” he concluded.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

- Ruchita Mehra | mehra.r@pg.com
- Paromita Kundu | kundu.p.1@pg.com

Investor Relations Contact:

- Flavia Machado | machado.f.1@pg.com